From 9bb65a1fdfbd9ae80b72c4a94be8f43ed9b72155 Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Wed, 18 Mar 2026 11:16:42 +0000 Subject: [PATCH] extract: 2026-01-01-openevidence-clinical-ai-growth-12b-valuation Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA> --- ...lue is immediate unambiguous and low-risk.md | 6 ++++++ ...t of US physicians daily within two years.md | 6 ++++++ ... diagnostic accuracy in randomized trials.md | 6 ++++++ ...evidence-clinical-ai-growth-12b-valuation.md | 17 ++++++++++++++++- 4 files changed, 34 insertions(+), 1 deletion(-) diff --git a/domains/health/AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk.md b/domains/health/AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk.md index b32496ab7..2bac828ac 100644 --- a/domains/health/AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk.md +++ b/domains/health/AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk.md @@ -49,6 +49,12 @@ The 92% figure applies to 'deploying, implementing, or piloting' ambient AI as o WVU Medicine expanded Abridge ambient AI across 25 hospitals including rural facilities in March 2026, one month after Epic AI Charting launch. This rural expansion suggests ambient AI has passed from pilot phase to broad deployment phase, as enterprise technology typically enters academic medical centers first, then regional health systems, then rural/critical access hospitals last. The fact that a state academic health system serving one of the most rural and medically underserved states chose to expand Abridge post-Epic launch provides implicit market validation of Abridge's competitive position. + +### Additional Evidence (extend) +*Source: [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] | Added: 2026-03-18* + +OpenEvidence demonstrates that clinical reasoning support (not just documentation) can achieve comparable adoption velocity: 40%+ of US physicians daily within two years, 20M consultations/month by January 2026. However, persistent trust barriers remain: 44% of physicians concerned about accuracy/misinformation and 19% concerned about lack of oversight, even among heavy users. This suggests adoption speed doesn't eliminate fundamental trust issues. + --- Relevant Notes: diff --git a/domains/health/OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md b/domains/health/OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md index 183513621..c36e659de 100644 --- a/domains/health/OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md +++ b/domains/health/OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md @@ -17,6 +17,12 @@ What makes this significant is the adoption speed. Reaching 40% of US physicians The incumbent response is UpToDate ExpertAI (Wolters Kluwer, Q4 2025), leveraging its trusted brand and install base. The competitive dynamic -- startup vs incumbent in clinical decision support -- will determine whether AI clinical knowledge becomes a winner-take-all market or fragments. + +### Additional Evidence (extend) +*Source: [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] | Added: 2026-03-18* + +OpenEvidence reached 20M clinical consultations/month by January 2026 (2,000%+ YoY growth from 8.5M/month in 2025), achieved 1M consultations in a single day on March 10, 2026, and is now valued at $12B (up from $3.5B, tripling in months). Used across 10,000+ hospitals nationwide. First AI to score 100% on all parts of USMLE. + --- Relevant Notes: diff --git a/domains/health/medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md b/domains/health/medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md index da1625c12..f474ce728 100644 --- a/domains/health/medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md +++ b/domains/health/medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md @@ -17,6 +17,12 @@ A deeper finding from a Stanford/Harvard study challenges even the "similar accu The implication for AI deployment strategy: the highest-value clinical AI applications are not diagnostic augmentation but workflow automation (ambient documentation, administrative burden reduction) and safety netting (AI triage catching missed findings). The centaur model may still apply to medicine, but the interaction design must prevent physicians from overriding AI on tasks where AI demonstrably outperforms -- a politically and ethically charged constraint. + +### Additional Evidence (challenge) +*Source: [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] | Added: 2026-03-18* + +OpenEvidence achieved 100% USMLE score and is now deployed at 20M consultations/month with 40%+ of US physicians using it daily, creating the first large-scale empirical test of whether benchmark performance translates to population health outcomes. However, no peer-reviewed outcomes data has been published despite this unprecedented scale of deployment. + --- Relevant Notes: diff --git a/inbox/archive/2026-01-01-openevidence-clinical-ai-growth-12b-valuation.md b/inbox/archive/2026-01-01-openevidence-clinical-ai-growth-12b-valuation.md index f865ea6e2..0f2645cbc 100644 --- a/inbox/archive/2026-01-01-openevidence-clinical-ai-growth-12b-valuation.md +++ b/inbox/archive/2026-01-01-openevidence-clinical-ai-growth-12b-valuation.md @@ -7,9 +7,13 @@ date: 2026-01-01 domain: health secondary_domains: [ai-alignment] format: company-announcement -status: unprocessed +status: enrichment priority: medium tags: [openevidence, clinical-ai, decision-support, physician-adoption, clinical-decision-support, health-ai, trust] +processed_by: vida +processed_date: 2026-03-18 +enrichments_applied: ["OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years.md", "medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials.md", "AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -68,3 +72,14 @@ This creates a two-track clinical AI story: (1) Abridge/ambient scribes for docu PRIMARY CONNECTION: [[OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years]] WHY ARCHIVED: Significant scale update — the existing claim understates 2026 metrics by an order of magnitude. Also: USMLE 100% creates the benchmark vs. outcomes tension in practice, not theory. EXTRACTION HINT: Update the existing claim with scale metrics, but flag the benchmark-to-outcomes translation tension as a challenge to both the OpenEvidence claim and the benchmark performance claim + + +## Key Facts +- OpenEvidence valued at $12B in January 2026 Series D (up from $6B three months prior, $3.5B in earlier round) +- 20M clinical consultations/month by January 2026, up from 8.5M/month in 2025 +- 1M consultations in one day on March 10, 2026 +- Used across 10,000+ hospitals and medical centers +- 44% of physicians concerned about accuracy and misinformation risk +- 19% of physicians concerned about lack of physician oversight or explainability +- First AI to score 100% on all parts of USMLE +- Series D: $250M led by Thrive Capital and DST Global